India's Orphan Drug Potential: 1,004 Rare Disorders, $100,000+ Treatments Await Solutions
GS2Polity · Governance · IR· Health policy & public health· Prelims + Mains·
Orphan drugs and healthcare accessibility: a GS2 Social Justice and Public Health case study.
Why in news
The article highlights India's potential to lead in orphan drug manufacturing for 1,004 rare genetic disorders, emphasizing the need for policy incentives to overcome high treatment costs.
Background
India reports 1,004 rare genetic disorders where annual treatment costs can exceed $100,000. The Orphan Drug Act of 1983 provides tax breaks and market exclusivity to incentivize development.
Facts for Prelims
- Act / BillOrphan Drug Act (1983): Provides tax breaks and market exclusivity for rare disease drugs
- FactIndia supports rare disease patients up to Rs 50 lakh
- FactU.S. approved 1,122 orphan drugs post-Act implementation by 2022
- FactIndia reports 1,004 rare genetic disorders
Prelims practice question
With reference to orphan drugs and rare genetic disorders in India, consider the following statements:
- India has reported a total of 1,004 rare genetic disorders.
- The Orphan Drug Act of 1983 provides market exclusivity and tax breaks to developers.
- India supports rare disease patients for costs up to Rs 1 crore.
Which of the statements given above is/are correct?
- (a)1 only
- (b)2 only
- (c)1 and 2 only
- (d)1 and 3 only
Show answer
Answer: (c) 1 and 2 only — Statements 1 and 2 are correct. Statement 3 is incorrect: India supports rare disease patients up to Rs 50 lakh.
For Mains
Q. Discuss the institutional and economic barriers in India's orphan drug manufacturing and suggest policy measures to make high-cost treatments accessible to patients.
Dimensions to cover in your answer
- Market failure: High R&D costs and small patient pools deter private investment without robust subsidies
- Regulatory bottleneck: Challenges in conducting clinical trials and manufacturing specialized drugs for rare genetic disorders
- Affordability gap: Disparity between high annual treatment costs ($100,000+) and public health support limits
Keywords: Orphan Drugs · Rare Genetic Disorders · Market Exclusivity · Pharmaceutical Manufacturing · Public Health Accessibility
More Social Justice notes
- Keralam government plans new Bill to make private health care more affordable · 6 October 2026
- Tamil Nadu allocates ₹812 crore to provide gold and silk sarees for eligible brides · 6 October 2026
- Karnataka to reserve 2% of government jobs for athletes across 34 disciplines · 5 October 2026
- Nara Lokesh orders 1,000 Andhra Pradesh schools to reach five-star status by 2029 · 5 October 2026
- Karnataka to use ₹2,000 crore ADB loan to strengthen 500 public schools · 5 October 2026
- KSRTC to host vending machines and incinerators at 14 terminals for menstrual needs · 5 October 2026
This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.